Mirae Asset Global Investments Co. Ltd. Has $4.41 Million Position in Twist Bioscience Co. (NASDAQ:TWST)

Mirae Asset Global Investments Co. Ltd. lowered its position in Twist Bioscience Co. (NASDAQ:TWST) by 22.6% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 119,544 shares of the company’s stock after selling 34,964 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Twist Bioscience were worth $4,406,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. boosted its position in Twist Bioscience by 81.7% during the first quarter. Envestnet Asset Management Inc. now owns 5,900 shares of the company’s stock worth $291,000 after purchasing an additional 2,653 shares during the period. US Bancorp DE boosted its position in Twist Bioscience by 11.8% during the first quarter. US Bancorp DE now owns 5,942 shares of the company’s stock worth $295,000 after purchasing an additional 626 shares during the period. MetLife Investment Management LLC boosted its position in Twist Bioscience by 81.2% during the first quarter. MetLife Investment Management LLC now owns 29,690 shares of the company’s stock worth $1,466,000 after purchasing an additional 13,308 shares during the period. Rhumbline Advisers boosted its position in Twist Bioscience by 12.1% during the first quarter. Rhumbline Advisers now owns 56,408 shares of the company’s stock worth $2,785,000 after purchasing an additional 6,110 shares during the period. Finally, BlackRock Inc. boosted its position in Twist Bioscience by 8.3% during the first quarter. BlackRock Inc. now owns 4,692,119 shares of the company’s stock worth $231,696,000 after purchasing an additional 358,217 shares during the period.

Twist Bioscience Price Performance

TWST opened at $29.24 on Tuesday. Twist Bioscience Co. has a 1-year low of $11.46 and a 1-year high of $43.21. The business has a 50 day moving average of $36.15 and a 200-day moving average of $29.89.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Friday, February 2nd. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.03. The firm had revenue of $71.50 million during the quarter, compared to analysts’ expectations of $67.59 million. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. Twist Bioscience’s quarterly revenue was up 31.8% compared to the same quarter last year. During the same period last year, the business earned ($0.74) earnings per share. Equities research analysts predict that Twist Bioscience Co. will post -3.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Emily M. Leproust sold 1,132 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $32.74, for a total value of $37,061.68. Following the completion of the transaction, the chief executive officer now directly owns 514,149 shares of the company’s stock, valued at $16,833,238.26. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Twist Bioscience news, CEO Emily M. Leproust sold 1,132 shares of the stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $32.74, for a total transaction of $37,061.68. Following the completion of the transaction, the chief executive officer now directly owns 514,149 shares in the company, valued at $16,833,238.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 1,128 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $33.52, for a total value of $37,810.56. Following the transaction, the chief executive officer now owns 515,281 shares of the company’s stock, valued at $17,272,219.12. The disclosure for this sale can be found here. Insiders sold a total of 11,037 shares of company stock valued at $384,092 over the last ninety days. 3.92% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Scotiabank upped their target price on Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research report on Monday, February 5th. Barclays reduced their price objective on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research report on Wednesday, April 10th. Finally, The Goldman Sachs Group raised Twist Bioscience from a “neutral” rating to a “buy” rating and increased their price objective for the company from $25.00 to $45.00 in a research report on Wednesday, January 17th.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.